Business Segments Cipla Limited

Stocks

CIPLA

INE059A01026

Pharmaceuticals

Market Closed - NSE India S.E. 15:53:30 07/09/2026 +04			5-day change	1st Jan Change
1,395.00 ^INR	+0.72%		-1.01%	-7.70%

09-03	India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar	RE
08-25	Cipla's Pithampur, India Unit Gets 7 Observations From US FDA	MT

Sales 2026 by Business Segment

© MarketScreener.com See more

Sales 2026 by Geography

© MarketScreener.com See more

Historical Breakdown of Revenue by Business Segments

Net Income: Breakdown by Business Segment

Geographical Revenue Distribution History

Breakdown by Business Segment (INR)

Fiscal Period: March	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Pharmaceutical Products
Pharmaceutical and Related Products						214B	220B	248B	264B	278B
Total Assets						-	-	-	-	425B
Interest Expense						-	-	-	-	-482M
Income Tax Expense						-	-	-	-	13.54B
CAPEX						-	-	-	-	-15.99B
EBT						-	-	-	-	52.24B
D&A						-	-	-	-	10.72B
Operating Income						39.44B	43.83B	60.56B	68.72B	-
Net Income						-	-	-	-	38.79B
New Ventures						5.32B	10.55B	11.12B	13.03B	-
Operating Income						-1.62B	-528M	-691M	105M	-
Inter Segment Revenue						-1.19B	-3.01B	-1.8B	-2.02B	-

Geographical breakdown of sales (INR)

Fiscal Period: March	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
India						98.28B	98.69B	109B	116B	127B
Total Assets						47.8B	50.23B	51.96B	59.69B	81.08B
						-	-	-	-	43.25B
United States of America						44.31B	59.09B	75.02B	78.99B	68.72B
Total Assets						29.57B	31.59B	33.2B	34.82B	40.44B
						-	-	-	-	42.85B
Rest of The World						48.72B	46.41B	49.69B	42.07B	43.25B
Total Assets						9.04B	5.58B	4.72B	3.94B	5.19B
						-	-	-	-	68.72B
South Africa						26.33B	23.35B	24.31B	38.26B	42.85B
Total Assets						20.27B	17.71B	20.69B	21.65B	24.63B
						-	-	-	-	127B

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!